

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known			
Application Number	09/977,878		
Filing Date	10/15/2001		
First Named Inventor	Marsha A. Moses		
Art Unit	1642		
Examiner Name	Karen A. Canella		
Attorney Docket Number	701039-054701		

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.1	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAL	AA	US-6,037,138	03-14-2000	Moses et al.	e
JX		US-			
	<u></u>	US-			
		US-			
		US-			
	ļ	US-			
	ļ	US-			
	<u> </u>	US-			
		US-			
		US-			
	<u> </u>	US-			
	ļ	US-			
<u> </u>		US-			
	—	US-			
ļ	ļ	US-			
l	1	US-	1		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Country Code' Number (If known)	MM-DD-YYYY	AM-DD-YYYY Figures A	Figures Appear	Τ*
KAZ	BA	WO 97/41441 A2, A3	11-06-1997	Children's Medical		
				Center Corporation	£	•
	ļ					
}	1				1	

Date Examiner prin Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at 222 uspto gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Inspires Translation is attached. possible. Applicant is to place a check mark here if English language Translation is attached.

2

Sheet

PANESHALL FOR FORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known			
Application Number	09/977,878		
Filing Date	10/15/2001		
First Named Inventor	Marsha A. Moses		
Art Unit	1642		
Examiner Name	Karen A. Canella		
Attorney Docket Number	701039-054701		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials Cite No. CA		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Baker, T. et al. "Serum metalloproteinases and their inhibitors: markers for malignant potential." Br J Cancer. 1994 Sep.; 70(3):506-12.				
	СВ	Garbisa, S. et al. "Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy." Cancer Res. 1992 Aug 15; 52(16):4548-9.				
	CC	Kleiner, D.E. et al. "Matrix metalloproteinases and metastasis." Cancer Chemother. Pharmacol. 1999; 43 Suppl:S42-51.				
	CD	Lochter, A. et al. "The significance of matrix metalloproteinases during early stages of tumor progression." Ann N Y Acad Sci. 1998 Oct 23; 857:180-93.				
	CE	Monier, F. et al. "Gelatinase isoforms in urine from bladder cancer patients" Clin. Chim. Acta. 2000 Sep; 299 (1-2):11-23.				
	CF	Moses, M. et al. "Increased incidence of matrix metalloproteinases in urine of cancer patients" Cancer Res. 1998 Apr 1; 58(7): 1395-9.				
	CG	Nakajima, M. et al. "Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762 NF mammary adenocarcinoma." Cancer Res. 1993 Dec 1; 53(23):5802-7.				
	СН	Yan, Li, et al. "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL" J Biol Chem. 2001 Oct 5;276(40):37258-65.				
	CI	Zucker, S. et al. "Plasma assay of matrix metalloproteinases (MMPs) and MMP inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment." Ann NY Acad. Sci. 1994 Sep 6; 732:248-62.				

Examiner Signature	garen	4.6	pulla	Date Considered	4/26/04

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.